Nintedanib* (VARGATEF®) is approved in the EU and in other countries worldwide in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumor histology after first-line chemotherapy.1 Nintedanib (OFEV®) is also licensed in the EU and other countries worldwide for the treatment of idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease.2 Different brand names may be used in countries outside the EU.
Nintedanib (VARGATEF®) summary of product characteristics, December 2019 (Accessed: June 2020).
Nintedanib (OFEV®) summary of product characteristics, April 2020 (Accessed: June 2020).
*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumor histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.
© 2020 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: June 2020
